{"filings":[{"id":99315,"accession_number":"0001140361-26-017637","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q1 revenue up 87% to $246M; raises 2026 guidance; olezarsen sHTG peak sales view >$3B","event_type":"earnings","confidence":"high","bullets":["Total revenue $246M (+87% YoY); GAAP operating loss $118M; non-GAAP loss $75M.","TRYNGOLZA net sales $27M; DAWNZERA $16M (+125% QoQ); royalties $58M, R&D revenue $138M incl. $95M milestones.","2026 guidance raised: total revenue $875-900M (from $800-825M); non-GAAP op. loss $425-475M (from $500-550M).","Olezarsen sHTG sNDA accepted for Priority Review (PDUFA June 30); peak net sales guidance raised to >$3B.","Zilganersen NDA for Alexander disease accepted Priority Review (PDUFA Sept 22); bepirovirsen NDA also accepted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":246091000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99314,"accession_number":"0001140361-26-015801","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ionis zilganersen meets primary endpoint in Alexander disease; PDUFA Sept 22, 2026","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: gait speed stabilized vs control at Week 61 (LS mean diff 33.3%, p=0.041) in patients ≥5 years.","GMFM-88 in children 2-4 years showed 22.9-point improvement vs control (nominal p=0.034).","Key secondary endpoints (MBS, PGIS, PGIC, CGIC) consistently favored zilganersen over control.","Serious TEAEs less frequent on zilganersen (37.5%) vs control (47.1%); most AEs mild/moderate.","FDA Priority Review with PDUFA action date set for September 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115245,"accession_number":"0001140361-26-008340","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Ionis announces retirement of two long-serving directors and appointment of Peter Reikes to board","event_type":"leadership","confidence":"high","bullets":["B. Lynne Parshall and Joseph Wender retiring at end of term in June 2026 after 25+ years on the board.","Peter N. Reikes to rejoin board effective June 4, 2026; he previously served from 2018-2021.","Reikes most recently senior strategy advisor for ARPA-H and senior advisor to FDA.","Both departing directors received Ionis Career Achievement Award; company thanks them."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115244,"accession_number":"0001140361-26-006718","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis FY2025 total revenue $944M (+34% YoY); guides 2026 rev $800-825M, op loss $500-550M","event_type":"earnings","confidence":"high","bullets":["FY2025 total revenue $944M (2024: $705M); Q4 revenue $203M.","TRYNGOLZA net sales $108M in first launch year; DAWNZERA $7M in first full quarter.","SPINRAZA royalties $212M, WAINUA royalties $49M; collaborative rev $508M incl $280M Ono upfront.","2026 guidance: revenue $800-825M, non-GAAP op loss $500-550M, cash ~$1.6B.","Olezarsen sNDA for sHTG submitted; zilganersen NDA for Alexander disease decision H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":203330000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115243,"accession_number":"0001140361-26-000893","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis reports TRYNGOLZA 2025 preliminary U.S. net sales of $105M, ups peak olezarsen guidance to >$2B","event_type":"earnings","confidence":"high","bullets":["TRYNGOLZA generated $105M in preliminary 2025 U.S. net product sales, outperforming expectations as first FDA-approved FCS treatment.","Annual peak net sales guidance for olezarsen in sHTG increased to >$2B from >$1B following strong Phase 3 data.","Submitted sNDA for olezarsen in severe hypertriglyceridemia; potential approval and launch anticipated in 2026.","Expects 2026 launches of zilganersen for Alexander disease (NDA in Q1) and bepirovirsen for chronic hepatitis B (with GSK).","Five Phase 3 readouts from partnered programs planned in 2026, including pelacarsen (Novartis) and eplontersen (AstraZeneca)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":203330000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115242,"accession_number":"0001140361-26-000435","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Bepirovirsen Phase 3 positive: primary endpoint met, functional cure rates superior to SOC","event_type":"other_material","confidence":"high","bullets":["Over 1,800 patients enrolled in two Phase 3 studies (B-Well 1 & 2) across 29 countries.","Bepirovirsen + SOC achieved statistically significant functional cure rates vs. SOC alone on all ranked endpoints.","Ionis eligible for up to $150M in regulatory/sales milestones plus 10-12% tiered royalties.","Global regulatory submissions planned from Q1 2026; potential first finite 6-month CHB therapy.","Drug has Fast Track FDA, Breakthrough Therapy China, and SENKU Japan designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131664,"accession_number":"0001193125-25-284609","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Ionis closes $770M 0% convertible notes offering, repurchases $200M of 2026 notes","event_type":"debt","confidence":"high","bullets":["Issued $770M aggregate principal of 0.00% Convertible Senior Notes due 2030 (including full greenshoe), net proceeds ~$751.2M.","Used ~$267.6M of net proceeds to repurchase $200M of existing 2026 convertible notes via concurrent transactions.","Remaining proceeds for further repurchases of 2026 notes and general corporate purposes.","Initial conversion rate: 10.1932 shares/$1,000, conversion price ~$98.10 (35% premium over Nov 12 close of $72.67).","Notes mature Dec 1, 2030, no regular interest, redeemable after Dec 6, 2028 if stock ≥130% of conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131663,"accession_number":"0001140361-25-041225","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ionis reports Phase 3 olezarsen results: 72% TG reduction, 85% fewer pancreatitis events","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: up to 72% placebo-adjusted mean reduction in fasting triglycerides at 6 months, sustained through 12 months (p<0.001).","85% reduction in acute pancreatitis events (p<0.001); 86% of patients achieved TG <500 mg/dL, below risk threshold.","Favorable safety profile; serious AEs lower in olezarsen (9-11%) vs placebo (14%); most common AE mild injection site reactions.","sNDA for 50 mg and 80 mg doses to be submitted to FDA by end of 2025; PDUFA target action date in 2026.","Data presented at AHA Scientific Sessions and simultaneously published in The New England Journal of Medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131661,"accession_number":"0001140361-25-040220","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K/A","filed_at":"2025-11-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ionis enters advisory agreement with retiring executive Richard Geary","event_type":"other","confidence":"high","bullets":["Advisory Services Agreement with Richard Geary effective Jan 16, 2026 through Feb 13, 2027.","Total fee of $300,000, plus up to $400/hour for hours over 16/week, capped at $450,000 total.","Geary will provide up to 16 hours/week of advisory services following retirement from Ionis.","Agreement includes standard confidentiality, non-solicitation, and invention assignment clauses.","Either party may terminate with 15 days' written notice; equity acceleration triggered on change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131662,"accession_number":"0001140361-25-039650","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q3 revenue $157M, up 17% YoY; raises FY 2025 guidance on TRYNGOLZA strength","event_type":"earnings","confidence":"high","bullets":["TRYNGOLZA Q3 net sales $32M, ~70% QoQ increase; FY guidance raised to $85-95M.","Olezarsen Phase 3 sHTG: 72% TG reduction, 85% AP reduction; sNDA by year-end 2025.","Zilganersen positive pivotal in Alexander disease; NDA submission planned Q1 2026.","Total revenue guidance raised to $875-900M; non-GAAP op loss guided to $275-300M.","Cash and investments $2.2B as of Sep 30; DAWNZERA launched in August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":740381000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148225,"accession_number":"0001140361-25-035634","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ionis reports positive pivotal study results for zilganersen in Alexander disease; NDA planned Q1 2026","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: gait speed improved 33.3% vs control (p=0.0412) at week 61 in 50 mg cohort.","No approved disease-modifying treatments for Alexander disease; first investigational drug to show positive impact.","Safety profile favorable: most adverse events mild/moderate; SAEs numerically lower in zilganersen arm.","NDA submission to FDA targeted for Q1 2026; evaluating U.S. Expanded Access Program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148224,"accession_number":"0001140361-25-033541","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ionis reports positive Phase 3 results for olezarsen in sHTG: 72% triglyceride drop, 85% pancreatitis reduction","event_type":"other_material","confidence":"high","bullets":["Olezarsen achieved 72% placebo-adjusted mean reduction in fasting triglycerides in Phase 3 CORE study (p<0.0001)","Olezarsen reduced acute pancreatitis events by 85% (p=0.0002) in pooled analysis of CORE and CORE2 studies","Over 90% of patients from CORE/CORE2 enrolled in open-label extension study","Ionis plans to submit sNDA to FDA for olezarsen in sHTG by end of year"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148223,"accession_number":"0001140361-25-032176","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves Ionis' DAWNZERA (donidalorsen) for HAE prophylaxis in patients 12+","event_type":"regulatory","confidence":"high","bullets":["First and only RNA-targeted HAE medicine; self-administered every 4 or 8 weeks via autoinjector.","Phase 3 OASIS-HAE: Q4W reduced monthly attack rate 81% vs placebo (primary endpoint); 87% from second dose.","OASISplus OLE: 94% attack rate reduction after one year; switch cohort reduced attacks 62% vs prior therapy.","Ionis' second independent launch in nine months; 84% of patients surveyed preferred DAWNZERA over prior treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148222,"accession_number":"0001140361-25-027949","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ionis Q2 revenue doubles to $452M; raises FY 2025 guidance, TRYNGOLZA sales $19M","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $452M (up from $225M); GAAP income from ops $140M vs loss $66M year ago.","TRYNGOLZA net product sales $19M in Q2, first half $26M; SPINRAZA royalties $54M, WAINUA royalties $10M.","FY 2025 guidance raised: total revenue $825-850M (from $725-750M); TRYNGOLZA sales guided at $75-80M.","Donidalorsen expected approval Aug 21, 2025; Phase 3 olezarsen sHTG data due September.","Received $280M upfront from sapablursen license; cash & investments $2.3B; CFO raised non-GAAP op loss guidance to $300-325M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":583660000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166994,"accession_number":"0001140361-25-022267","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ionis CDO Richard Geary retiring Jan 2026; Holly Kordasiewicz to succeed","event_type":"leadership","confidence":"high","bullets":["Richard Geary, EVP & chief development officer, will retire effective January 2026 after 30 years at Ionis.","Holly Kordasiewicz, currently SVP neurology, to become EVP & chief development officer in January 2026.","Geary led 50+ IND submissions and 6 FDA/EU approvals including TRYNGOLZA; will stay as strategic consultant in 2026.","Kordasiewicz has 20 years R&D experience and played key role in QALSODY and IONIS-MAPT Rx Alzheimer's program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166993,"accession_number":"0001140361-25-022001","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Ionis annual meeting: all director nominees elected; equity plan increased by 4M shares","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected: Diaz (134.5M for), Hayden (133.3M), Klein (127.1M), Loscalzo (108.8M).","Say-on-pay resolution approved with 132.6M votes in favor (95.9% of votes cast).","Amendment to 2011 Equity Incentive Plan approved; authorized shares increased by 4M to 42.5M.","Ratification of Ernst & Young as 2025 independent auditors approved with 144.6M votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166992,"accession_number":"0001140361-25-019620","cik":874015,"company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ionis announces positive Phase 3 Essence study of olezarsen in moderate hypertriglyceridemia","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: placebo-adjusted 61% (80 mg) and 58% (50 mg) reduction in TG at 6 months (p<0.0001).","Met all key secondary endpoints; majority of participants achieved normal TG <150 mg/dL.","Favorable safety profile; most common AE was mild injection site reactions.","Study enrolled 1,478 participants with moderate HTG on standard-of-care lipid-lowering therapy.","Pivotal Phase 3 CORE and CORE2 data in sHTG expected Q3 2025; potential sNDA filing by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}